PositiveID acquires Easy Check Medical Diagnostics
DELRAY BEACH, Fla. PositiveID on Wednesday acquired the intellectual property rights and assets of Easy Check Medical Diagnostics in an effort to expand its portfolio of noninvasive glucose-level testing products and diabetes management tools under development.
“Existing solutions in diabetes care are painful and have mediocre compliance rates,” stated Scott Silverman, PositiveID chairman and CEO. “With our current portfolio of products under development, we are hopeful we can improve diabetics’ lives while helping them manage their healthy glucose levels, thereby decreasing the risk of diabetes-related complications and reducing medical costs.”
Easy Check presently has two primary products under development: the Easy Check breath glucose detection system and the iGlucose wireless communication device.
The Easy Check breath glucose test is a non-invasive glucose detection system that measures acetone levels in a patient’s exhaled breath. The association between acetone levels in the breath and glucose is well documented, the company noted, but previous data on the acetone/glucose correlation has been insufficient for reliable statistics. Easy Check’s breath glucose detection system combines a proprietary chemical mixture of natrium nitroprussid with breath exhalate, which is intended to create a new molecular compound that can be measured with its patent-pending technology. This product, if approved by the Food and Drug Administration, could eliminate a patient’s need to prick his or her finger multiple times per day to get a blood sugar reading.
Easy Check’s other product under development, its iGlucose system, uses wireless SMS messaging to automatically communicate a diabetic’s glucose readings to the iGlucose online database. iGlucose is intended to provide next-generation, real-time data to improve diabetes management and help ensure patient compliance, data accuracy and insurance reimbursement. In addition, PositiveID believes that the iGlucose wireless communication device is the first to address the Medicare requirement for durable medical equipment manufacturers and pharmacies to maintain glucose level logs and records for the millions of high-frequency diabetes patients.